One in three women with a HER2‐positive pure DCIS lesion develops a subsequent HER2‐negative invasive breast cancer (Visser et al., 2019), although the clonal relationship between primary and recurrent lesions was not investigated in that study. This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.